ASX:EMD Emyria (EMD) Stock Price, News & Analysis → One trade. One ticker. One week. (From Wealthpin Pro) (Ad) Free EMD Stock Alerts Add Compare Share Share Today's Range N/A50-Day Range N/A52-Week Range N/AVolume471,333 shsAverage VolumeN/AMarket CapitalizationN/AP/E RatioN/ADividend YieldN/APrice TargetN/A Stock AnalysisStock Analysis Get Emyria alerts: Email Address Ad Wealthpin ProOne trade. One ticker. One week. Do you want to target weekly income of up to $2k or more… Starting with just $500... With just one trade per week? Well, then you should click here to see this free training. About Emyria Stock (ASX:EMD)Emyria Limited, a clinical-stage biotech company, engages in the development of treatments for unmet medical needs. The company develops psychedelic-assisted therapy, as well as MDMA drug discovery program. Its drug development program includes EMD-RX5 for treatment of psychological distress and mild stress and anxiety. The company was formerly known as Emerald Clinics Limited and changed its name to Emyria Limited in September 2020. Emyria Limited was founded in 2018 and is headquartered in Leederville, Australia.Read More Ad Wealthpin ProOne trade. One ticker. One week. Do you want to target weekly income of up to $2k or more… Starting with just $500... With just one trade per week? Well, then you should click here to see this free training. EMD Stock News HeadlinesApril 11, 2024 | finance.yahoo.comUS March deficit shrinks as outlays fall, tax receipts riseApril 10, 2024 | finance.yahoo.comEmyria opens Empax Centre to target care gaps in resistant PTSDApril 24, 2024 | Crypto Swap Profits (Ad)He Is Giving Away BitcoinAnd my special guest is willing to give you $10 in Bitcoin (BTC) if you take it seriously. Right now is a very important time to pay attention to what we are doing and what is happening. If you wait... it will be too late. This week we are holding several workshops and if you attend and pay attention my special guest is going to send you $10 in Bitcoin.January 29, 2024 | finance.yahoo.comEmyria Slides As Insider Purchases Lose Another AU$300kJanuary 14, 2024 | au.investing.comEmyria kicks off year with $2.5 million R&D incentive on the heels of Authorised Prescriber statusJanuary 10, 2024 | proactiveinvestors.com.auSEC gives Bitcoin ETFs the long-awaited green lightJanuary 10, 2024 | proactiveinvestors.com.auEmyria sharpens focus on delivering MDMA treatments for PTSD patientsJanuary 10, 2024 | msn.comClosing Bell: The ASX got slow-boiled like a frog in a pot to close at -0.69pc downApril 24, 2024 | TradeSmith (Ad)The A.I. story nobody is telling you (Read ASAP)There's been a lot of buzz surrounding A.I. over the past year... Most of it is just hype and speculation. But there's one recent A.I. development you NEED to hear about...January 9, 2024 | msn.comASX Health Stocks: Emyria surges 19pc after granting of ‘Authorised Prescriber’ status by TGANovember 21, 2023 | proactiveinvestors.com.auEmyria welcomes top healthcare leader as chairmanNovember 12, 2023 | proactiveinvestors.com.auEmyria restructures board amid cost efficiency commitmentNovember 9, 2023 | finance.yahoo.comIt's Unlikely That Shareholders Will Increase Emyria Limited's (ASX:EMD) Compensation By Much This YearOctober 30, 2023 | proactiveinvestors.com.auEmyria secures ethics endorsement for MDMA Authorised Prescriber application, clearing way for TGA decisionOctober 26, 2023 | finance.yahoo.comEmyria hails strong growth in clinical billingsOctober 21, 2023 | proactiveinvestors.com.auEmyria given green light to import MDMA for therapeutic trials in AustraliaOctober 5, 2023 | au.investing.comEmyria completes entitlement offer, raises $1.18m ahead of MDMA-assisted therapy trialSeptember 26, 2023 | finance.yahoo.comEmyria set to begin MDMA study after securing local supplySeptember 7, 2023 | finance.yahoo.comEmyria provides unique combination of drug development and therapy deliverySeptember 4, 2023 | msn.comClosing Bell: Liontown’s kitty is sitting pretty; Benchmark makes most of Monday ahead of RBA meetSeptember 4, 2023 | proactiveinvestors.com.auEmyria raises $2 million in placement; launches $3.1 million entitlement offerSeptember 3, 2023 | msn.comTop 10 at 11: Emyria soars on funding news, and loads of tasty stuff unearthed in Canada.September 1, 2023 | finance.yahoo.comEmyria Full Year 2023 Earnings: AU$0.018 loss per share (vs AU$0.027 loss in FY 2022)August 1, 2023 | finance.yahoo.comEmyria advances development and commercialisation of unique drug productsJuly 11, 2023 | proactiveinvestors.com.auEmyria recruits first patient for MDMA-assisted therapy trialJuly 3, 2023 | proactiveinvestors.com.auEmyria expands mental health care capabilities with Pax Centre acquisitionJune 8, 2023 | proactiveinvestors.com.auEmyria hails ethics approval for MDMA-assisted clinical trialSee More Headlines Receive EMD Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Emyria and its competitors with MarketBeat's FREE daily newsletter. Email Address Industry, Sector and Symbol Stock ExchangeASX SectorMedical Industry Health Information Services Sub-IndustryN/A Current SymbolASX:EMD CUSIPN/A CIKN/A Webwww.emeraldclinics.com.au Phone61 8 6559 2800FaxN/AEmployeesN/AYear FoundedN/AProfitability EPS (Most Recent Fiscal Year)A($0.04) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-11,950,000.00 Net MarginsN/A Pretax MarginN/A Return on Equity-380.72% Return on Assets-33.63% Debt Debt-to-Equity Ratio311.99 Current Ratio0.56 Quick Ratio2.69 Sales & Book Value Annual Sales$1.95 million Price / Sales0.00 Cash FlowN/A Price / Cash Flow6.67 Book ValueN/A Price / BookN/AMiscellaneous Outstanding Shares366,630,000Free FloatN/AMarket CapN/A OptionableNot Optionable Beta0.70 Metaverse Stocks And Why You Can't Ignore ThemThinking about investing in Meta, Roblox, or Unity? Click the link to learn what streetwise investors need to know about the metaverse and public markets before making an investment.Get This Free Report Key ExecutivesDr. Michael WinloMD & DirectorDr. Alistair VickeryExecutive Medical Director & DirectorMr. Joseph Daniel Ohayon ACAMBA Intl Bus., Chief Financial OfficerMs. Sara PolanskiCommunications & Brand ManagerMs. Tracie ErnenweinHead of Research & Drug DevelopmentMary-Ann RennieHead of Corporate OperationsMs. Susan Patricia Park A.C.A. (Age 49)A.C.I.S., ACSA, AGIA, B.Com., F Fin, FCIS, Company Secretary More ExecutivesKey Competitors1st GroupASX:1STAclarionNASDAQ:ACONWAlcidion GroupASX:ALCArcturis DataOTCMKTS:SSYNFArtryaASX:AYAView All CompetitorsInsidersAlistair VickerySold 25,488 sharesTotal: $1,758.67 ($0.07/share)Michael WinloBought 200,000 shares on 8/8/2023Total: $19,200.00 ($0.10/share) This page (ASX:EMD) was last updated on 4/24/2024 by MarketBeat.com Staff From Our PartnersConflict In Israel Sends Gold Soaring ???? Here’s How To Get Your ShareColonial MetalsThe A.I. story nobody is telling you (Read ASAP)TradeSmithtop AI stock (it’s not MSFT, GOOGL, AMZN or AAPL)Traders AgencyDid You Get Your Free Bitcoin Yet?Crypto Swap ProfitsBitcoin Rockets To Record High But Buy THIS InsteadParadigm PressExposed: 10 CENT Crypto to Explode April 20th?True Market InsidersThe #1 Crypto for 2024InvestorPlaceDon’t Miss Out on the AI Gold Rush That’s Just Getting StartedBanyan Hill Publishing Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Emyria Limited Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
